Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
AUTOR(ES)
Conchon, Monika, Freitas, Carla Maria Boquimpani de Moura, Rego, Maria Aparecida do Carmo, Braga Junior, José Wilson Ramos
FONTE
Revista Brasileira de Hematologia e Hemoterapia
DATA DE PUBLICAÇÃO
2011
RESUMO
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
Documentos Relacionados
- What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
- Monitoring imatinib plasma concentrations in chronic myeloid leukemia
- Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
- Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
- Influence of late treatment on how chronic myeloid leukemia responds to imatinib
